Cardiovascular Complications of Carfilzomib (ICARE)

European Georges Pompidou Hospital

Status: Unknown

Conditions: Hypertension; Heart Failure; Myeloma

Study type: Observational

Funder types: Other

Identifiers

NCT04407858

00011928 ICARE

Details and patient eligibility

About

Cardiovascular toxicity of carfilzomib, a last generation proteasome inhibitor, is highly incident according to retrospective data. Prospective cohort study of patients initiated on carfilzomib.

Enrollment: 60 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Intention to treat by Carfilzomib

Exclusion criteria

• History of carfilzomib treatment